U.K. trails EU neighbors in insulin pump use, report shows; FDA approves oral brain hemorrhage drug;

> A recent report found that the U.K. trails nearby countries such as Germany and Norway in the use of insulin pumps, with only 7% of Type 1 diabetes patients using them. In those countries, about 15% of patients use the delivery devices, and 40% in the U.S. opt for a pump, according to the report. Story

> The FDA approved Arbor Pharmaceuticals' Nymalize, the first nimodipine oral solution for brain hemorrhage patients. It was previously available as a liquid-filled gel capsule. Report

> Korean researchers have developed a new nanoparticle contrast medium to diagnose cancer that releases an anti-cancer drug and targets the tumor on-site. In mice, tumors shrunk 90% in 48 hours. Story

> Scientists at the Indian Institute of Science in Bangalore have created a needleless vaccine delivery system that uses supersonic shock waves to innoculate patients painlessly. Article

> Halo Pharma and Altus Forumulation have joined forces to create a series of drugs based on Altus' drug delivery technologies that include high-dose delivery, taste-masked controlled release liquids and tamper- and abuse- resistant medicines. Release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.